Completed OBSERVATIONAL NCT04651920

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

A Study on Association Between Homologous Recombination Genes and the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer

Sponsor: Lei Li

Conditions BRCA1 Mutation BRCA2 Mutation Chinese Epithelial Ovarian Cancer Homologous Recombination Deficiency Homologous Recombination Genes Prognosis

Interventions Evaluation of homologous recombination deficiency score

Updated 5 times since 2021 Last updated: Mar 26, 2022 Started: Nov 26, 2020 Primary completion: Mar 26, 2022 Completion: Mar 26, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates BRCA1 Mutation and BRCA2 Mutation and is currently completed. Lei Li leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Apr 2022 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Dec 2021 — Apr 2022 [monthly]

Recruiting
Jan 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China